Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-63776

ABSTRACT: Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq]

PROVIDER: E-GEOD-63776 | ExpressionAtlas | 2019-05-14

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Similar Datasets

Homo sapiens

Project description:Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq]

| PRJNA269148 | ENA

Altering cancer transcriptomes using epigenomic inhibitors

Project description:Altering cancer transcriptomes using epigenomic inhibitors

| PRJNA269931 | ENA

Homo sapiens

Project description:Altering cancer transcriptomes using epigenomic inhibitors [Illumina beadchip]

| PRJNA269947 | ENA

Transcriptome innovations in primates revealed by single-molecule long-read sequencing

Project description:We produced an extensive transcript catalog for LCLs of 5 primate species by leveraging isoform sequencing and short-read RNA-seq. The curated transcriptomes were used to assist mass spectrometry protein identifications.

2022-05-31 | PXD031213 | Pride

Bos taurus

Project description:Comparison of the bovine embryonic transcriptomes using RNA-Seq

| PRJNA134751 | ENA

12 transcriptomes of three life stages using RNA-Seq

Project description:12 transcriptomes of three life stages using RNA-Seq

| PRJNA589551 | ENA

Genomic Characterization of Metastatic Castration Resistant Prostate Cancer

Project description:<p>Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC).</p>

| phs001648 | dbGaP

Homo sapiens

Project description:Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]

| PRJNA268320 | ENA

BET inhibitors suppress BZLF1 expression [MutuI RNA-seq]

Project description:BET inhibitors suppress BZLF1 expression [MutuI RNA-seq]

| PRJNA328391 | ENA

Chemical profiling of the genome with anti-cancer drugs defines target specificities

Project description:Many anti-cancer drugs induce DNA breaks to eliminate tumor cells. The anthracycline topoisomerase II inhibitors can also evict histones. We performed a genome-wide high-resolution mapping of chemotherapeutic effects of various topoisomerase I and II inhibitors. We show that different drugs target different types of chromatin for induction of DNA damage and histone eviction. Topoisomerase inhibitors topotecan and etoposide similarly target transcriptionally active chromatin for DNA damage. Daunorubicin induces DNA breaks and evicts histones in active chromatin, thus quenching local DNA damage response. The analog aclarubicin evicts histones in H3K27me3-marked heterochromatin. These results can guide rational treatment decisions regarding these genome manipulating anti-cancer drugs. FAIRE-seq and g-H2AX ChIP-seq were performed on K562 cells after drug exposure

2015-05-10 | E-GEOD-60395 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data